Numenos key facts
as of Oct 2026- Developer of an artificial intelligence clinical trial development platform designed to uncover new biology and biomarkers that predict patient response.
- Numenos is valued at approximately $21.8M as of Oct 2026 (last reported valuation).
- It has raised $7.7M; the latest was Seed Round ($7.7M) in Jan 2025.
- Notable investors include Dhuna Ventures, Meron Capital, TechAviv Founder Partners.
- Status: Privately Held (backing).
Numenos's last reported valuation, Jan 2025. Nothing priced has surfaced since.
- ·Watch Numenos: the Monday email on marks, rounds and moves
Numenos funding rounds
No funding rounds for Numenos are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Numenos
3Numenos valuation
Numenos's last reported valuation was $21.8 million in Jan 2025. No priced round, secondary trade or fund mark has surfaced since.
Numenos investors
3 investors are on record for Numenos, including Dhuna Ventures, Meron Capital and TechAviv Founder Partners.
About Numenos
Developer of an artificial intelligence clinical trial development platform designed to uncover new biology and biomarkers that predict patient response. The company's platform specializes in detecting biomarkers early in clinical trial development, facilitating cheaper and more successful phase-III clinical trial design, enabling healthcare sector to reduce the cost and time of clinical trials.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2023
- Employees
- 14
- Website
- numenos.ai/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.